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Background
Evolving data link juvenile idiopathic arthritis (JIA) to environmental
factors and gut microbes, which may trigger the innate immune sys-
tem through bacterial lipopolysaccharides. We hypothesized that
children with new onset JIA have increased intestinal bacterial trans-
location and endotoxinemia.
Methods
65 new onset, systemic treatment naive JIA patients (polyarticu-
lar JIA, n = 21, oligoarticular JIA, n = 29 and spondylarthropathies,
n = 15) and 14 healthy controls participated in the study. We
determined the plasma immunoglobulin reactivity against Escher-
ichia coli lipopolysaccharide (LPS). We measured the levels of
lipopolysaccharide binding protein (LBP), and alpha-1-acid glyco-
protein (A1AGP), which are acute phase proteins related to
intestinal bacterial translocation, and C-reactive protein (CRP).
Assays were performed using commercial EIA kits (Hycult, R&D
systems) or laboratory-prepared LPS.
Results
Children with polyarticular JIA have statistically significant in-
creased concentrations of circulating anti-LPS antibodies, LBP,
CRP, and A1AGP compared to healthy controls (p < 0.05). The
concentration of LBP, CRP and A1AGP in patients with polyarti-
cular JIA significantly differs from the oligoarticular JIA group
(p < 0.05), but not spondylarthropathies. Spondylarthropathy
patients have increased circulating anti-LPS antibodies com-
pared to healthy controls (p < 0.05). There are no statistically
significant differences between oligoarticular JIA patients and
healthy controls. LBP and A1AGP levels correlate with CRP levels
(r = 0.787 and r = 0.635 respectively).
Conclusions
Children with polyarticular JIA and spondylarthropathies have evi-
dence of increased exposure to gut bacteria, as reflected by anti-
LPS antibodies and LBP. The degree of exposure is proportional
to the degree of systemic inflammation. These data imply that
the intestine maybe the source of stimulation for the immune
system in JIA.© 2016 The Author(s). Open Access This artic
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Background
Oral pathogens that cause periodontitis have been implicated as trig-
gers for rheumatoid arthritis (RA), with antibodies to bacterial citrulli-
nated proteins (ACPA) suggested as a potential mechanism for the
transfer of oral inflammation to the joints. Although periodontitis is
rare in children, gingivitis, present in 50 % of adolescents, is a
chronic inflammatory precursor to periodontitis. Patients with juven-
ile idiopathic arthritis (JIA) rarely produce ACPA, but patients with
polyarticular JIA who carry the ACPA, are considered to have more
aggressive arthritis, similar to adult RA patients. Because adult RA is
associated with gingival inflammation and periodontitis, we tested
for an association between ACPA and dental clinical outcomes in JIA.
Our study objectives were to test for increased frequency of gingi-
vitis in children with JIA compared to controls, and to test for correla-
tions between ACPA and dental clinical outcomes in JIA patients and
dental controls.
Methods
This was a cross-sectional study of 85 patients with JIA, 62 dental pa-
tient controls and 11 healthy patient controls at the Seattle Children’s
Hospital (SCH) Rheumatology and Dental Clinics. Serum from an add-
itional historic cohort of 30 healthy children was used to study ACPA.
Rheumatologists and dentists completed the oral and joint exams
blinded to each other’s findings. ACPA were detected with a com-
mercial CCP3 assay and also to 29 citrullinated full length proteins or
peptides within these proteins using a custom Bio-Plex bead array.
For each peptide, elevated levels were defined to be values largerle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
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were defined to have elevated ACPA if they had elevated levels for
more than 4 of the proteins. The prevalence of elevated ACPA was
compared across groups using the chi-squared test.
Results
Although JIA patients overall had better oral health than controls
(lower indices for plaque, caries and gingivitis), they had signifi-
cantly more bleeding on probing of the gingiva, the most spe-
cific sign of active inflammation (percentage of sites bleeding
17 % vs 8 %, p = 0.007). There was no correlation between JIA
disease activity or immunosuppression with dental indices. ACPA
were detected in only three JIA patients by commercial CCP3
assay, but elevated levels were detected by the custom array in
15/41 (37 %) of poly JIA, 14/36 (39 %) of oligo JIA, and 19/57
(33 %) of dental controls. Antibodies to more than 4 citrullinated
peptides were most common in poly JIA 9/41 (22 %) compared
with 1/36 (3 %) for oligo JIA, and 2/57 (4 %) for dental controls,
(p = 0.002 by chi-squared test). We found no associations be-
tween ACPA status and any dental index.
Conclusions
Gingival inflammation was associated with JIA, suggesting a systemic
immune response could be triggered by oral bacteria involved in
both oral and synovial inflammation. More sensitive and specific tests
for ACPA may lead to improved prognosis and understanding of the
triggers for arthritis in children.
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Background
Juvenile dermatomyositis (JDM) is recognized as a systemic auto-
immune vasculopathy. While more rare than and juvenile idio-
pathic arthritis (JIA), JDM shares common features with JIA (e.g.,
many JDM patients have arthritis) and each is representative of
the spectrum of rheumatic disease manifestations in children.
However the pathogenesis of these diseases remains to be fully
solved. More research is needed to identify disease-specific bio-
markers for diagnosis and monitoring of pediatric rheumatic dis-
eases. Anti-endothelial cell antibodies (AECA) have been detected
in rheumatic diseases such as Kawasaki disease, however, roles
and functions of AECA are still uncertain. Multiple studies have
reported a relationship between inflammation and endothelial
cell functions (Nat Rev Immunol. 2007; 7:803). We aimed to de-
tect target antigens for AECA in patients with pediatric rheumatic
diseases comprehensively by proteomics and investigated clinical
and diagnostic significance of them.
Methods
To detect target antigens on endothelial cells for AECA, we separated
proteins extracted from human aortic endothelial cells (HAEC) by
two-dimensional electrophoresis (2DE) and then transferred them
onto membranes. Antigens that were positive only in pediatric
rheumatic disease sera from three patients with JDM and two pa-
tients with JIA but not in healthy donor sera were detected by west-
ern blotting (WB). The detected proteins were identified using
peptide mass finger-printing. Bound IgG antibodies to HAEC antigens
were detected using standard methods.
Results
We detected eighteen protein spots as pediatric rheumatic disease-
specific autoantigens by 2DE-WB. We successfully identified 738
proteins out of these spots that were candidate targets of autoanti-
bodies in pediatric rheumatic diseases. Antibodies appeared to target
proteins with specific functions, e.g., ATP-related proteins (37 %),
muscle-related proteins (19 %), calcium regulated protein and/orcalcium binding proteins (13 %) and redox related proteins (10 %).
Furthermore, half of the identified target antigens represented mem-
brane proteins. Among the 738 candidate HAEC autoantigens were
myosin light polypeptide 6 (MYL6) and myosin-9 (MYH9). IgG auto-
antibodies to MYL6 were detected in 20 % of the patients with JDM
(n = 61) using ELISA assays. However, 50 % of the untreated JDM
patients with active disease (n = 10) had anti-MYL6 antibodies, in
contrast to 12 % (p < 0.05) of the patients with JIA (n = 17) and in
16 % (p = 0.05) of control children (n = 25) tested on the same ELISA
assays. IgG autoantibodies to MYH9 were detected in 31 % of the
active patients with JDM (n = 35), (50 % of the untreated JDM
patients with active disease), in comparison to 27 % of the patients
with JIA (n = 15) and 12 % (p < 0.05) of control children.
Conclusions
IgG antibodies to MYL6 and MYH9 were detected in the sera from
patients with pediatric rheumatic diseases, respectively. These anti-
bodies might be useful markers for pediatric rheumatic diseases.
Proteomic approaches are a powerful tool for identifying target anti-
gens for AECA.
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Background
Response to methotrexate (MTX), one of the main treatments for
juvenile idiopathic arthritis (JIA), is highly variable in these patients.
The mechanisms that lead to poor MTX response remain ill-defined.
The aim of this study was to identify a gene expression transcrip-
tional signature associated with poor response to MTX in children
with JIA.
Methods
RNA extracted from peripheral blood mononuclear cells (PBMC)
collected from 47 patients with JIA prior to MTX treatment and
14 age-matched controls was sequenced. Unsupervised clustering
and pathway analysis was then performed. Biological differences
between all JIA patients and controls were explored by constructing a
signature of differentially expressed genes. Transcriptional profiles were
compared to a reference gene expression database representing sorted
cell populations, including B, T and monocytes.
Results
A signature of 99 differentially expressed genes (Bonferroni-cor-
rected p < 0.05) capturing the biological differences between all
JIA patients and controls was identified. Unsupervised clustering
of samples based on this list of 99 genes identified subgroups
enriched for MTX response status. Comparing the gene signature
to reference signatures from sorted cell populations revealed high
concordance between the expression profile of monocytes and
that of MTX non-responders. CXCL8 (IL-8) was significantly upreg-
ulated in JIA patients compared to controls (Bonferroni-corrected
p = 4.12 × 10-10). A direct search for genes differentially expressed
between all MTX responders and all MTX non-responders identi-
fied six genes (ADAMTS2, FOSL1, F3, NR4A3, NFKBID, CD83) with
Bonferroni-adjusted p-values <0.05. However, this gene signature
did not predict overall response status.
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The variability in clinical response to methotrexate in JIA pa-
tients is associated with differences in gene transcripts modu-
lated in monocytes. Pre-treatment PBMC gene expression
profiles may serve as useful biomarkers predictive of methotrex-
ate responsiveness.P5
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Background
Polyarticular juvenile idiopathic arthritis is a complex trait character-
ized by gene-environment interactions. While we are beginning to
identify multiple genomic regions associated with disease risk in JIA,
most of that risk is located within non-coding regions of the gen-
ome. Thus, to develop a mechanistic understanding of how genetic
variance contributes to JIA, we require a detailed understanding of
the non-coding genome and the functional elements located within
these regions.
Methods
We created a multidimensional genomic map for juvenile idio-
pathic arthritis (JIA). Using genome-wide methylation sequencing,
whole genome sequencing on the Illumina 10x platform, RNA
sequencing, and chromatin immunoprecipitation-sequencing for
informative histone marks (H3K4me1 and H3K27ac), we provide
new insights into the interaction between genetic variation, the
epigenome, and gene expression in the context of a common
human disease.
Results
The epigenomes of JIA neutrophils display numerous differences
from those from healthy children. DNA methylation changes,
however, had only a weak effect on gene expression. In contrast,
H3K4me and H3K27ac marks, commonly associated with enhancer
functions, strongly correlated with gene expression. Furthermore,
although some unique/novel enhancer marks were associated
with insertion-deletion events (indels) identified on whole gen-
ome sequencing, genetic variation could account for no more
than 30 % of the JIA-specific epigenome. Treatment with metho-
trexate was associated with a re-ordering of transcription associ-
ated with changes in both methylation and histone marks,
including histone and methylation marks located within indels.
This finding demonstrates the plasticity of the epigenome in this
setting. Alterations in histone marks most strongly associated
with the transcriptional changes that accompanied the initiation
of therapy.
Conclusions
JIA represents a complex genetic-epigenetic trait characterized by
aberrant transcription in pathologically relevant cells. Initiation of
effective therapy is associated with significant re-ordering of the epi-
genome, even in genomic regions where there is underlying genetic
variance.P6
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Despite the advances in treating children with juvenile idiopathic arth-
ritis (JIA), still a proportion of such patients may be resistant to treat-
ment with the current modalities including methotrexate and biologics.
It is possible that the lack of response to treatment in some patients is
due to a difference in the underlying pathophysiology, i.e. the driving
cytokine rather than the actual severity of the disease.
Methods
The records of 16 children with different forms of JIA, all of whom were
resistant to treatment with methotrexate, prednisolone, Anti-TNF and
anti-IL1 were reviewed in order to analyze the response they had after
treatment with tocilizumab over a period of 24 months. All patients
received tocilizumab intravenous infusions according to a standard
protocol, bi-weekly for patients with systemic JIA and monthly for poly-
articular JIA. The following clinical and laboratory response parameters
were recorded at regular interval: number of joint with active arthritis,
number of joints with limited range of motion, parent global assess-
ment of disease activity, physician global assessment of disease activity,
functional class, hemoglobin level, erythrocyte sedimentation rate
(ESR), C reactive protein (CRP).
Results
The mean age of this group of patients was 14 years, the mean age
at diagnosis was 8 years, and the mean duration of disease before
initiation of tocilizumab treatment was 7 months. 54 % of the chil-
dren had systemic JIA while the 46 % remaining had polyarticular
JIA. Of the polyarticular JIA patients 43 % were rheumatoid Factor
(RF) positive. 94 % of the patients had received prior methotrexate,
75 % steroids and 88 % etanercept. The remainder were ankinra
19 %, Adalimumab 13 %, rituximab 13 % and infliximab 6 %. The
mean ESR and CRP showed a dramatic drop in the first 3 months
(from 60 mm/hr to less than 20, and from 9.2 to less than 0.8 re-
spectively). The mean hemoglobin rose from 11.8 gm/l to 13.8 gm/l.
The mean physician and parent global assessment of disease activity
showed significant improvement. Lastly, the mean number of joints
with active arthritis and joints with limited range of motion fell from
8 and 4 respectively to two or less joints at 3 months after starting
treatment. No serious adverse events were noted, only one patient
had grade 2 neutropenia while 2 children had a mild increase in total
cholesterol level. No cases of severe or unusual infections were re-
ported during the 24 month period.
Conclusions
The dramatic response to tocilizumab in this group of patients with
severe JIA resistant to conventional DMARDs, anti-TNF or anti-IL1
therapy may indicate that the disease process in such patients may
not be refractory to therapy but in fact is driven by a different cyto-
kine, in this case IL6. We conclude that when faced with a JIA patient
with apparent resistance to treatment switching between different
classes of biologics may produce a better outcome.
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Background
In July 2015, the CARRA Registry was re-established as a multi-center
observational study that collects essential data from persons with
pediatric onset rheumatic diseases. The primary objective is to evalu-
ate the safety of therapeutic agents. Key secondary objectives are to
document the clinical courses and drug treatment patterns of
Pediatric Rheumatology 2016, Volume 14 Suppl 1 Page 4 of 16patients and to evaluate clinical outcomes and their determinants,
including treatment and other factors. This abstract describes the
clinical characteristics of the patients in the CARRA Registry at the
time of enrollment.
Methods
The CARRA Registry enrolled patients with juvenile idiopathic arthritis
(JIA) from CARRA pediatric rheumatology care centers throughout
the United States. To facilitate cohort studies within the Registry,
there was preferential enrollment of patients who were newly diag-
nosed or who newly initiated treatment with methotrexate or a bio-
logic agent. Patients with systemic JIA were also preferentially
enrolled. Following the initial launch of the Registry, patients with a
history of at least 5 joints affected were preferentially enrolled as
well. Data at enrollment for all patients enrolled prior to December
31, 2015 were included. Missing values were ignored.
Results
Up to December 31, 2015, there were 445 patients enrolled in the
CARRA Registry from 41 different CARRA centers. The clinical charac-
teristics of the patients at enrollment are shown. With respect to co-
hort establishment, 105 patients were enrolled within 6 months of
their diagnosis of JIA and 96 patients initiated methotrexate or bio-
logic therapy at the time of enrollment. The numbers of patients cur-
rently using methotrexate and specific biologic agents at enrollment
are shown.
Conclusions
The CARRA Registry successfully enrolled 445 patients with JIA during
the first 6 months of operation while the number of activated sites
was still accumulating. The current enrollees are enriched for early
disease and recent medication initiations, making them ideal subjects
for highly informative observational studies. Prospectively collected
data from the CARRA Registry will enable rigorous and robust real-
world studies of medication safety and disease outcomes.
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Background
Little information is available on the relative ability of researchers at
smaller institutions to participate in clinical research. A perception ex-
ists that it is less possible to be successful in that setting than at lar-
ger centers. In pediatric rheumatology a large fraction of specialists
and patients are in small center settings. Advancement of the field
would be enhanced by the inclusion of more investigators and more
patients.
Methods
The CARRA Registry, intended to create a comprehensive registry of
all patients with pediatric rheumatic disease, provided support to de-
velop research infrastructure at small as well as large centers.
Throughout the 3-year active history of the Registry, monthly up-
dates compiled information about numbers of enrolling centers, new
subject enrollments and data collection, follow up visit data collec-
tion, and completeness of collected clinical information forms.
We compared the performance of investigators at small and large
centers participating in the CARRA Registry. Information at several
time points was separated by center size, and totals and per-
investigator averages were calculated. Additionally, a compilation of
scientific publications based on Registry data was analyzed for
authorship, and number of co-authors from small and large centers
was compared.
Results
9560 total subjects were enrolled in the CARRA Registry at the
59 included participating sites, and data were collected from a
total of 41127 patient visits. Small pediatric rheumatology centerscomprised 42 % of enrolling sites and 24 % of enrolling investi-
gators. 2416 or 24 % of all enrolled subjects came from small
centers. There were no differences in per-investigator perform-
ance between providers at small or large centers in any of the
data collection parameters measured: number of new enroll-
ments; number of visits collected per patient; or completeness
(quality) of the submitted data forms. The results were compar-
able at all time points evaluated. The pace of collection slowed
toward the end of the study period, but the rate was the same
between small and large centers. A difference was observed in
the number of co-authors from small or large centers on publica-
tions arising from the CARRA Registry; investigators from small
centers were relatively under-represented (only 14.3 % from small
centers vs. 85.7 % from large).
Conclusions
Investigators at smaller centers can contribute data of equal quantity
and quality to that obtained at institutions with more established re-
search infrastructures. The support CARRA provided in laying the
groundwork for research participation at small centers may have
contributed to enhancing their inclusion in the registry. However,
small-center investigators were under-represented in publications
arising from the Registry. The reasons are unclear, but the missed op-
portunity to achieve academic rewards from research participation
may contribute to the perception among investigators at small cen-
ters that research is less possible in that setting.
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Background
Patients with membranous lupus nephritis (MLN) make up 8-30 %
of pediatric LN cases. For patients diagnosed initially with pure
class V LN, risk of progression to proliferative LN is difficult to as-
certain, given variable treatment practices and the limited avail-
ability of data from repeat renal biopsies. Although consensus
guidelines for management of LN have been formulated, these
recommendations are based on evidence from adult studies, and
treatment of pediatric LN is largely empirical. The degree of vari-
ability in current treatment practices for patients with pediatric
class V LN is largely unknown.
Methods
Subjects with pediatric systemic lupus erythematosus (SLE) and class V
lupus nephritis (LN) from the Childhood Arthritis and Rheumatology
Research Alliance (CARRA) Legacy Registry were included. Demo-
graphic, disease and medication-related data were collected between
2010 and 2014 from 59 CARRA Legacy Registry sites. Data were utilized
to describe demographic, clinical, and treatment characteristics in this
cohort.
Results
A total of 132 subjects had MLN, either in isolation or in combin-
ation with proliferative LN. Seventy-four subjects had pure class V
LN. The proportion of subjects with daily corticosteroid treatment
was similar among groups (96 %, 91 %, and 96 %, for class III +
V, IV + V, and V, respectively, P = 0.67). Proportion of subjects
exposed to mycophenolate was significantly different among
groups, with a trend toward more frequent mycophenolate
exposure in the pure class V group (83 %, 74 %, 92 % for class
III + V, IV + V, and V, respectively, P = 0.045). Proportion of subjects
exposed to any disease-modifying antirheumatic drug (DMARD)
or biologic was similar among the three groups (83 %, 91 %,
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tion of subjects with decreased glomerular filtration rate (less
than 90 ml/min/1.73 m2 ) was significantly different among
groups (4 %, 38 %, and 4 %, for class III + V, IV + V, and V, re-
spectively, P < 0.0001).
Conclusions
To date, this is the largest reported cohort of children with MLN.
Practice patterns may vary among centers and may not reflect the
published LN consensus treatment guidelines. More research is
needed to confirm the trends observed in this analysis of the CARRA
Legacy Registry data.
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Background
Lupus anticoagulant hypoprothrombinemia syndrome (LA-HPS) is
a rare condition that may predispose to both thrombosis and
bleeding due to positive lupus anticoagulant (LA) and factor II
deficiency. The syndrome is more common in the pediatric popu-
lation in association with systemic lupus erythematosus (SLE); the
majority of patients require immunosuppressive medications as a
steroid-sparing agent. The purpose of this case series was to re-
port the use of RTX in the treatment of LA-HPS in pediatric SLE
(pSLE).
Methods
Medical records of pSLE (≤18 years old) cases that fulfilled American
College of Rheumatology (ACR) criteria and were treated with RTX
for LA-HPS after glucocorticoid (GC) induction at both institutions
were reviewed retrospectively from January 2010 to February 2016.
Information obtained in a systematic fashion included demographics,
laboratory findings, clinical course, RTX dose/duration, medications,
pre/post RTX LA, pre/post RTX factor II levels and outcomes at 1 year
follow-up.
Results
As of February 2016, we identified 3 cases. All cases presented with
bleeding (one with additional thrombosis) and were treated with
pulse or high dose methylprednisolone and RTX with complete or
clinical resolution of LA-HPS at 1 year follow-up.
Conclusions
Our systematic review of the 3 pSLE LA-HPS cases suggests that RTX:
a) is an effective steroid sparing agent for LA-HPS; b) does not affect
LA positivity; c) improves or normalizes Factor II levels.
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Background
Complementary and alternative medicines (CAM) are widely used in
the general pediatric population, and are disproportionately used in
children with musculoskeletal (MSK) conditions. In this study, we
identified factors associated with use of CAM therapies in children
with MSK conditions. We hypothesized that parental education, par-
ental CAM use and a history of depression, anxiety or stress would
be associated with child CAM use.Methods
We analyzed data from the 2012 National Health Interview Survey,
including the child CAM use supplement. We defined musculoskel-
etal conditions as the presence of arthritis, sprain, and back, neck,
muscle, bone, or joint pain, or use of CAM therapies for these condi-
tions. We constructed a logistic regression model with use of CAM
therapy as the outcome and the following covariates and predictors:
age, sex, region, race, school days missed, health status, insurance
category, presence of anxiety, depression or stress, highest educa-
tional status of one parent, parental CAM use, and ratio to poverty
threshold. We also analyzed perceived usefulness of CAM therapies
for MSK conditions.
Results
The total number of children with MSK conditions was 1,489,
representing 4,161,797 U.S. children. 49 % were female with a
mean age of 13.2. Controlling for multiple covariates in a logis-
tic regression model, many factors were positively associated
with CAM use: presence of depression, anxiety, or stress (OR
1.35, p = 0.028), parental CAM use (OR 2.80, p <0.001), parental
education higher than high school (OR 4.59, p <0.001), female
status (OR 1.51, p = 0.004), and location in the Western region
of the U.S (OR 1.74, p =0.027). Black race was inversely associ-
ated with CAM use (OR 0.35, p <0.001). Furthermore, a majority
of children (63.5 %) felt that CAM use helped their condition a
great deal, and 89.7 % felt that CAM use helped a great deal or
some.
Conclusions
Certain demographic factors and the presence of depression, anxiety
or stress are associated with CAM use in children with MSK condi-
tions. These children appear to have a high rate of response, though
sample size was insufficient to compare statistically to other condi-
tions. In the future, understanding if (and if so, which) children with
MSK conditions are more responsive to CAM therapies might help to
guide management of their symptoms.
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Background
Consensus treatment plans (CTPs) for induction treatment of newly
diagnosed proliferative lupus nephritis (LN) in juvenile SLE have been
developed to alleviate some of the decision-making burden and het-
erogeneity of this disease. However, patients who do not fully re-
spond to any of the regimens or develop disease flare after
remission require escalation of treatment. In this study, we took the
first step in developing CTPs for refractory proliferative LN and flare
by determining current practices of pediatric nephrologists and rheu-
matologists in US and Canada.
Methods
Members of CARRA and the American Society for Pediatric
Nephrology (ASPN) were surveyed in November 2015 to assess
treatment choices (other than modifying steroid dosing) and
level of agreement between rheumatologists and nephrologists
for proliferative LN patients. 2 cases were presented: 1) patients
refractory to induction treatment with corticosteroid and cyclo-
phosphamide (CYC) and 2) patients who flare after initial re-
sponse to induction.
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75 nephrologists and 37 rheumatologists completed the refractory
LN case survey questions. There were 3 scenarios at 7 months into
treatment including elevated creatinine with persistent hematuria
and nephrotic syndrome; nephrotic syndrome with mild hematuria
and improved creatinine; and persistent hematuria with improved
creatinine and proteinuria. In the scenario of elevated creatinine at
follow up, 44 % of rheumatologists and 42 % of nephrologists agreed
with the top choice of mycophenolate mofetil (MMF) + rituximab
(RTX). CYC + RTX (27 % vs. 16 %) and MMF alone (20 % vs. 20 %)
were the next most common choices for therapy in this situation. In
the scenario of persistent proteinuria, both rheumatologists and
nephrologists chose MMF alone (37 % vs. 41 %) and MMF + RTX
(34 % vs. 15 %). In the scenario of persistent hematuria, both rheu-
matologists and nephrologists chose MMF alone (38 % vs. 59 %) and
MMF + RTX (35 % vs. 11 %)[Ev1] 63 nephrologists and 33 rheumatol-
ogists completed the survey questions for the LN case for flare after
achieving remission on induction therapy. For LN flare after CYC in-
duction, rheumatologists chose CYC + RTX (36 %) or CYC alone
(21 %), whereas nephrologists chose CYC alone (22 %) or increased
the MMF (22 %). For LN flare after MMF induction, rheumatologists
chose CYC (27 %) or MMF + RTX (24 %), and nephrologists chose in-
creased MMF (38 %) or CYC (23 %). For LN flare with renal insuffi-
ciency and biopsy-confirmed rapidly progressive GN with significant
activity and chronicity, rheumatologists and nephrologists agreed
that CYC with or without RTX (78 % vs. 65 %) was the best thera-
peutic choice, although more rheumatologists would use combin-
ation CYC + RTX (57 % vs. 22 %).
Conclusions
Pediatric rheumatologists and nephrologists agree on treatment of
severe cases of proliferative LN refractory to induction therapy or LN
flare after remission. However, there were differences in choice of
therapies in the milder cases, specifically in the use of rituximab.
Further investigation will be necessary to delineate the reasons
behind this finding. This study highlights the importance of collab-
orative effort in developing CTPs for pediatric LN.
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Background
Pediatric rheumatologists have successfully improved the life expect-
ancy and quality of life of children with systemic lupus (cSLE). cSLE
has higher disease severity and morbidity than adult SLE, resulting in
the need to address transition to Adult Rheumatology. The conse-
quences of poor transition are loss of continuity in care and medica-
tion regimens resulting in worse disease activity and damage. As
data are scarce on successful transition of cSLE patients to adult care,
we conducted a pilot study to better understand how to facilitate
transition of cSLE patients to adult care.
Methods
Patients with cSLE ≥14 years old who fulfilled ACR SLE criteria
were evaluated using a 29-item Transition Readiness Question-
naire (SLE-TRQ) adapted from cystic fibrosis and sickle cell transi-
tioning questionnaires. It included skills (medical and life skills),
knowledge (medical and independent living), and psychological
factors (feelings, stress about transition). A protocol based on the
American Association of Pediatrics guidelines for successful transi-
tion was implemented for patients ≥18 years old. All patients
met with the adult rheumatologist in the pediatric clinic andwere accompanied to their first visit to the adult clinic by the Pediatric
Rheumatology nurse. A successful transition was defined as ≥ 3 visits
with the adult rheumatologist. All successfully transitioned patients
were asked to complete a Satisfaction Questionnaire.
Results
40 patients with a mean age of 18.4 years (range 14-26) completed
the SLE-TRQ. The mean disease duration was 5.25 years; 75 % were
female; 45 % Hispanic, 40 % African American, 7 % Caucasian. There
were 93 % who had major organ involvement, 19 (48 %) renal dis-
ease, 8 (20 %) neuropsychiatric lupus, 3 (10 %) abnormal pulmonary
function tests and 2 (5 %) anti-phospholipid syndrome. Eleven pa-
tients were on prednisone, median dose 20 mg/day (2.5-60 mg/day)
at the time of enrollment. Over 50 % were noncompliant at least on
one occasion with medications and appointments. For the SLE-TRQ,
27 patients self-reported good medical and independent living skills,
14 good knowledge, and 16 uneasiness/unreadiness for transition.
The mean scores were: skills- 1.39, knowledge- 2.4 and feelings about
transition- 2.3, where scores of 4-5 identify patients that are not
ready, 2-3 patients in preparation and 0-1 ready for transition. Eight
patients remain under pediatric care, scheduled to transition at a
later date. Of the 20 patients scheduled to transition, 12 successfully
transferred. The mean SLE disease activity index at the last pediatric
visit was 5.6 and at the third adult visit 5.25. Three patients were on
prednisone (mean dose 13.8 mg/day). Nine patients completed the
Satisfaction Questionnaire, reporting satisfaction with the transition
process.
Conclusions
This is the first study evaluating self-reported pre-transition readiness
in cSLE. Patients had good medical knowledge and independent liv-
ing skills but some were not ready to transition. We were able to suc-
cessfully transition 60 % of the patients suggesting adolescents with
cSLE and major organ involvement need additional support in the
transition to adult rheumatology.
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Elizabeth D. Mellins, Rayfel Schneider and Yukiko Kimura contributed
equally to this work.
Objectives
We aimed to identify (1) demographic/clinical characteristics; (2)
medication usage trends; (3) variables associated with worse disease
activity; and (4) characteristics of patients with persistent chronic
arthritis, in the Childhood Arthritis and Rheumatology Research Alli-
ance (CARRA) legacy Registry systemic JIA cohort.
Methods
Demographics, disease activity measures and medications at enroll-
ment of systemic JIA patients in the CARRA Registry were analyzed
using descriptive statistics. Multivariate analyses were conducted to
identify associations with increased disease activity. Medication
usage frequencies were calculated by year.
Results
528 systemic JIA patients were enrolled (2010-2013). 435 patients
had a complete dataset; of these, 372 met ILAR criteria and were in-
cluded in the analysis. At enrollment, median disease duration and
joint count were 3.7 years and 0 respectively; 16.4 % had rash and
6.7 % had fever. 26 % were taking IL-1 inhibitors and 29 % glucocor-
ticoids. DMARD and TNF inhibitors use decreased, while IL-6 inhibitor
use increased between 2010 and 2013. African-American (AA)
Pediatric Rheumatology 2016, Volume 14 Suppl 1 Page 7 of 16patients had worse joint counts (p = 0.003), functional status (p =
0.01) and physician global assessment (p = 0.008). Of 255 subjects
with >2 years disease duration, 56 % had no arthritis or systemic
symptoms, while 32 % had persistent arthritis only.
Conclusions
Most patients in the largest systemic JIA cohort reported to date had
low disease activity. Practice patterns for choice of biologic agents
appeared to change over the study period. Nearly 1/3 had persistent
arthritis without systemic symptoms >2 years after onset. AA race
was associated with worse disease activity. Strategies to improve out-
comes in subgroups with poor prognosis are needed.
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Background:
Systemic Juvenile Idiopathic Arthritis (systemic JIA) is commonly
treated with glucocorticoids (GC) alone, or methotrexate (MTX) or
biologic medications (most commonly IL1 or IL6 inhibitors), alone or
in combination with GC. The most effective treatment for new onset
systemic JIA is not known. The Childhood Arthritis and Rheumatol-
ogy Research Alliance (CARRA) developed standardized consensus
treatment plans (CTPs) of these therapies for untreated systemic JIA.
These CTPs will be used to better understand the comparative effect-
iveness of these treatments. A pilot study was conducted to assess
the feasibility of using the CTPs for this purpose using an observa-
tional registry.
Methods:
New onset untreated systemic JIA patients (pts) were enrolled in
the CARRA Registry and treated using the CTP selected by the
treating physician and patient/family (GC alone; MTX ± GC; IL1 in-
hibitor (IL1i) ± GC; IL6 inhibitor (IL6i) ± GC. An aggressive taper
was suggested if GC was started, with the goal of reducing the
dose to <50 % of the starting dose by 3 mos. Standard of care
intervals were used as data collection time points. The primary
outcome was clinically inactive disease (CID) off all GC at the
9 month visit. The CTPs were compared using chi square, Fisher’s
exact, and Wilcoxon rank sum tests.
Results:
30 patients were enrolled at 13 sites. 8 were started on a non-
biologic (2 GC, 6 MTX) and 22 on a biologic (12 IL1i and 10 IL6i). One
patient was lost to follow up. CTP choice appeared to segregate pri-
marily by site. No major differences in demographic or disease fea-
tures were found between each CTP group. The primary outcome
was achieved by 41 % of patients overall (11 of 27) on whom we
have 9 month visit data. 0 of 7 patients started on a non-biologic
CTP (GC or MTX) achieved the outcome, while 11 of 20 (55 %) of
those started on a biologic CTP (IL1i and IL6i) did (p = 0.022). There
were 3 serious adverse events: 2 infections requiring hospitalization
while receiving IL1i (1 patient was on GC and had cellulitis; the otherwas hospitalized for Grade 2 varicella and treated with IV acyclovir as
a precaution) and 1 macrophage activation syndrome (MAS) requir-
ing hospitalization (on IL6i). There was an additional Grade 2 MAS
episode in an IL1i treated patient. All patients recovered without
sequelae.
Conclusions:
The CARRA systemic JIA CTP pilot study was completed success-
fully. The patients were reasonably balanced at baseline between
CTP groups, and the primary determinants of CTP choice ap-
peared to be site and physician preference rather than patient
characteristics. Those initially treated with biologics had a greater
likelihood of achieving clinical inactive disease off GC at 9 months.
Having demonstrated feasibility of the CTPs, additional patients
will be enrolled as part of a larger comparative effectiveness
study to determine the most appropriate treatment strategy for
new onset systemic JIA.
Reference
[1] Y Kimura, T Beukelman, E Morgan-DeWitt, KL Mieszkalski, TB Graham,
MF Ibarra, N Ilowite, MS Klein-Gitelman, K Onel, S Prahalad, MG Punaro,
S Ringold, D Toib, H Van Mater, PF Weiss, L Schanberg and the
CARRA Registry Investigators. Results from the Childhood Arthritis
and Rheumatology Research Alliance Systemic JIA Consensus
Treatment Plans Pilot Study. Arthritis Rheumatol 2015;67;Suppl 10:
abstract 959
P16
A systemic review of pain relief modalities in juvenile idiopathic
arthritis: First step in developing a novel decision support
intervention
Timothy S. H. Kwok1, Jacinthe Bisaillon2, Christine Smith3, Lucie
Brosseau4, Jennifer Stinson5, Adam M. Huber6, Ciaran M. Duffy7,
Karine Toupin April8
1Undergraduate Medical Education, Faculty of Medicine, University of
Ottawa, Ottawa, Ontario, Canada; 2School of Nursing Sciences, Faculty of
Health Sciences, University of Ottawa, Ottawa, Ontario, Canada; 3School
of Epidemiology, Public Health and Preventive Medicine, Faculty of
Medicine, University of Ottawa, Ottawa, Ontario, Canada; 4School of
Rehabilitation Sciences, Faculty of Health Sciences, University of Ottawa,
Ottawa, Ontario, Canada; 5Hospital for Sick Children, Lawrence S.
Bloomberg Faculty of Nursing University of Toronto, Toronto, Ontario,
Canada; 6IWK Health Centre, Department of Pediatrics, Dalhousie
University, Halifax, Nova Scotia, Canada; 7Department of Pediatrics,
Faculty of Medicine, University of Ottawa, Children's Hospital of Eastern
Ontario Research Institute, Ottawa, Ontario, Canada; 8Children's Hospital
of Eastern Ontario Research Institute, Department of Pediatrics, Faculty
of Medicine, School of Rehabilitation Sciences, Faculty of Health
Sciences, University of Ottawa, Ottawa, Ontario, Canada
Correspondence: Timothy S.H. Kwok (tkwok016@uottawa.ca) –
Undergraduate Medical Education, Faculty of Medicine, University of
Ottawa, Ottawa, Ontario, Canada
Pediatric Rheumatology 2016, 14(Suppl 1):P16
Background
In juvenile idiopathic arthritis (JIA), although mainstay pharmaco-
logical therapy is useful in reducing disease activity, pain often per-
sists in a subset of patients. As such, effective pain management
utilizes a multidisciplinary approach, involving pharmacological,
physical, nutritional and psychological modalities. Due to the com-
plexity in pain relief modalities, there is a need for an intervention to
help youth with JIA and their parents make informed decisions that
are consistent with their values and preferences regarding these
treatments. The first step in creating a robust evidence-based patient
decision aid is to systematically review the evidence for these modal-
ities in JIA.
Methods
Major databases (Medline, Embase, PsycInfo, the Cochrane Library
and AMED) were searched for randomized controlled trials (RCTs) of
interventions in JIA compared to any control group that used pain as
an outcome measure from inception of the databases to the end of
May 2015. For each study, the mean change in pain intensity and
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dardized mean difference (SMD) was calculated using Review
Manager.
Results
361 citations were found after removal of duplicates. A total of 18
RCTs were included. RCTs were found for massage, splints and orth-
oses, therapeutic exercises, psychosocial modalities, non-steroidal
anti-inflammatory drugs (NSAIDs), disease-modifying anti-rheumatic
drugs (DMARDs) and biologics. Effective non-pharmacological pain
relief modalities included massage compared with relaxation therapy
(SMD = 2.88 (1.55,4.2)), custom-made orthoses compared with off-
the-shelf shoe inserts (SMD = 1.66 (0.76,2.56)) and with supportive
shoes (SMD = 1.55 (0.68,2.41)), pilates compared with a conventional
exercise program (SMD = 1.5 (0.86,2.13)), fitted foot orthoses (FOs)
with customized chair-side corrections compared with FOs without
any corrections (SMDs = 0.86 (0.33,1.39)) and an internet-based self-
management program compared with telephone support (SMD =
0.81(0.21,1.41)). Effective pharmacological pain relief modalities
included DMARDS (e.g., methotrexate, D-penicillamine, hydroxychlor-
oquine) compared with placebo (SMDs = 0.44 (0.06, 0.82) to 0.76
(0.36, 1.16)) and biologics (e.g., tocilizumab, abatacept) compared
with placebo (SMDs = 0.92 (0.54, 1.29) to 1.15 (0.5, 1.81)).
Conclusions
This systematic review shows that a wide variety of modalities are
effective in reducing pain in JIA. However, high heterogeneity in
patient characteristics, treatment regimen, as well as control inter-
ventions in trials underlines the importance of discussing the rele-
vance of the evidence before including it in a decision aid. The next
step aims to conduct a consensus meeting with patients, clinicians
and researchers to determine the content and format of the decision
aid, including its evidence-based information.
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Background
Systemic Lupus Erythematosus (SLE) is a multisystem chronic auto-
immune illness. In South Africa (SA), pediatric SLE (pSLE) patients
have worse outcomes compared to peers in North America and re-
quire specialized medical care with long term follow up. The aim of
this study was to describe caregivers’ experiences engaging in
chronic medical care for SLE, and to identify barriers and facilitators
to patient retention in care. Findings from this study can inform in-
terventions to improve chronic care of pediatric SLE patients in SA.
Methods
In-depth, semi-structured interviews were conducted with 22 care-
givers of pediatric SLE patients recruited from three centers in Cape
Town, SA in 2014. Interviews were audio-recorded, transcribed, and
analyzed for themes related to barriers to diagnosis.
Results
Four themes were identified and classified under caregiver or health
system barriers to chronic care engagement and retention, and three
themes were identified as facilitators. Barriers identified were a know-
ledge gap regarding SLE, financial barriers to care, and the social
stigma of SLE, and the complexity of the SA medical system. Chronichealth care facilitators identified were patient/parent education, a
robust support system for caregiver, and financial support for the
patient and caregiver.
Conclusions
Caregivers in this study reported challenges in returning for long
term care of SLE in their children. Improving family education at
diagnosis and visits may increase patient-physician trust, empower
patients and caregivers, and motivate them to return for care. Sup-
plementing travel cost for families may mitigate the largest financial
and time burden and improve patient retention.
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Background
Aim: To evaluate the feasibility of conducting comparative effective-
ness studies in jLS and identify potential confounders for evaluating
treatment response. JLS is a rare chronic disease that often causes
major morbidity for the growing child including hemiatrophy,
arthropathy, and seizures.
Methods
We conducted a prospective observational cohort study of juven-
ile localized scleroderma subjects who were beginning treatment
with one of 3 standardized regimens (consensus treatment plans
[CTPs]). The CTPs were: methotrexate alone, methotrexate with
intravenous pulse methylprednisolonge, and methotrexate with
oral corticosteroids. Choice of CTP was up to the subject’s phys-
ician. Subjects were evaluated with standardized activity and
damage assessment forms at 6 visits over 1 year. The majority of
the data was entered into the web-based legacy CARRA registry;
some paper study forms were collected to aid with evaluating
clinical assessment tools and additional patient and parent health
related quality of life measures. The primary outcome was to as-
sess the feasibility of enrolling patients. Secondary aims were to
explore the performance of developed clinical tools for evaluating
clinical state and treatment response, and assess the value of
other HRQOL questions. Data was analyzed by descriptive statis-
tics, correlation analyses, factor analysis, linear regression, and
Bayesian methods.
Results
Physicians at 10 CARRA sites enrolled between 1 and 9 subjects (me-
dian 5.5) into all 3 CTPs. The target enrollment of 50 subjects was
reached, with enrollment finishing 26 months after study initiation.
The actual enrollment period was 16 months, with initiation of enroll-
ment at each site delayed for 10-17 months by time required for IRB
and contract approval. The average rate of subject accrual was 3.1
subjects/month during the active enrollment period. There were no
significant differences between subjects in the different CTPs for age,
gender, race, or ethnicity; most were white, non-hispanic girls with a
median age of 13 years, and median disease duration of 13 months.
Most were new to treatment with systemic immunosuppressants. At
baseline, over 70 % of subjects had extracutaneous involvement,
with 32 % having joint involvement and 46 % having a growth
Pediatric Rheumatology 2016, Volume 14 Suppl 1 Page 9 of 16difference. Significant differences were found between subjects in
the different CTPs for disease duration, prior treatment with systemic
immunosuppressants, LS subtype, and some types of extracutaneous
involvement.
Conclusions
We achieved our primary outcome of showing the feasibility of con-
ducting comparative effectiveness studies in jLS, a rare disease. We
reached our target enrollment and enrolled subjects into all 3 CTPs.
We identified a much higher rate of extracutaneous and severe mor-
bidity than has previously been reported, possibly related to detailed
prospective data collection. Identifying potential confounders will
help determine appropriate sample size for conducting full-scale jLS
comparative effectiveness studies.
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Background
Periodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis
(PFAPA) syndrome is the most common periodic fever syndrome of
childhood, and tonsillectomy is reported to be curative in many
patients. The objective of our study was to compare the histologic
features of palatine tonsils surgically removed from children with
PFAPA and those with obstructive sleep apnea (OSA).
Methods
Age-matched patients with PFAPA and OSA who had undergone
tonsillectomy at Vanderbilt University Medical Center from 2000-
2015 were recruited. Participants’ archival paraffin-embedded,
formalin-fixed palatine tonsil tissue blocks were obtained. The fol-
lowing histologic features were measured after hematoxylin and
eosin (H&E) staining: average germinal center area, mantle width,
interfollicular distance, crypt width, and surface squamous epithe-
lium width. Representative areas of germinal centers, crypts, and
surface squamous epithelium were assembled on tissue microar-
rays, and immunohistochemical stains for lymphoid and myeloid
cells were performed. Staining was assessed with digital image
analysis. Features of matched PFAPA and OSA tonsils were com-
pared using the Wilcoxon-signed ranks test, and associations of
histologic features and time from the last episode were com-
pared with Spearman’s test.
Results
Sixteen cases with PFAPA and 16 controls with OSA were re-
cruited. Histologic measurements from PFAPA and OSA tonsils are
compared. Tonsils from patients with PFAPA had significantly
smaller germinal centers, less variation in germinal center area,
and wider surface squamous epithelia than those of patients with
OSA. Percentages of B and T lymphocytes, macrophages, and
dendritic cells were not significantly different in the germinal
centers, crypts, and squamous epithelium of PFAPA and OSA ton-
sils. Among PFAPA patients, longer time from the last fever epi-
sode was associated with larger germinal center area (Spearman’s
rho = 0.61, p = 0.02); however, this association did not remain
significant with multivariable analysis.
Conclusions
Germinal centers in tonsils from patients with PFAPA did not exhibit
hyperplasia, but the tonsillar surface squamous epithelium of PFAPA
patients was wider compared with children with OSA. In tonsils fromPFAPA patients, the germinal centers appeared to enlarge with time
after the last episode, suggesting that tonsillar architecture may
evolve with time during fever cycles. We plan to further study
lymphocyte activation, proliferation, and migration in the tonsils of
PFAPA patients to understand the mechanism of these histologic
differences.
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Background
Juvenile dermatomyositis (JDM) is a chronic inflammatory disorder of
the skin and striated muscle. A subset of patients can present with
rash only, labeled as skin predominant JDM (spJDM) for this study.
The natural course of patients with spJDM and optimal treatment is
unknown. The purpose of this study is to describe the clinical course
of spJDM patients and assess for early indicators that may predict
progression to classic JDM.
Methods
A chart review to identify patients presenting with spJDM was per-
formed on all patients with the diagnosis code for dermatomyositis
seen at 3 CARRA sites (Children’s Hospital of Wisconsin, Boston Chil-
dren’s Hospital, IWK Health Centre). Data collected included patient
demographics, presenting symptoms and exam findings, initial treat-
ment, muscle enzymes, muscle biopsy, electromyography, and mag-
netic resonance imaging (MRI). Patients were categorized as either
amyopathic (no weakness on exam and no diagnostic studies con-
sistent with myositis) or hypomyopathic (no weakness but diagnostic
studies showed subclinical myositis). Follow up visits were reviewed
for development of weakness.
Results
Twenty-four patients presented with spJDM: 8 (33 %) were amyo-
pathic on initial evaluation, while 16 (67 %) were hypomyopathic.
None of the amyopathic patients later developed weakness
(follow up 3-144 months, median 31 months). Six (38 %) hypo-
myopathic patients later evolved into classic JDM with weakness
(follow up 10-85 months, median 45 months). Time to develop-
ment of weakness ranged from 3 to 24 months after onset of
rash. Patients who developed weakness had varying degrees of
subclinical myositis as evidenced by lab or MRI. MRI was abnor-
mal in 7 of 20 patients (35 %) at baseline. Only 2 of these 7
patients (29 %) later developed weakness. Patients with an ab-
normal MRI were more likely to receive systemic corticosteroids
and/or methotrexate as part of initial therapy (43 % vs 8 %). The
combination of hydroxychloroquine (HCQ) with a topical calcine-
urin inhibitor was the most common first line agent (21 %). How-
ever, whether alone or in combination with a topical agent, HCQ
was initiated in 46 % of patients. Nine percent of patients treated
with HCQ with or without topical agents developed weakness,
while 50 % treated with topical agents alone and 40 % treated
with systemic steroids developed weakness. Methotrexate was
always started in conjunction with systemic steroids (4/24). Two
patients with no initial treatment were later treated with HCQ or
topical steroid for persistent skin disease and never had
weakness.
Conclusions
Our work suggests that topical therapies do not prevent the de-
velopment of weakness, but systemic treatment with HCQ may
diminish the development of weakness in spJDM (50 % vs 9 %).
Pediatric Rheumatology 2016, Volume 14 Suppl 1 Page 10 of 16No amyopathic patient progressed to develop weakness, while
38 % of hypomyopathic patients developed weakness. This sug-
gests the importance of comprehensive baseline testing using
clinical, lab and MRI assessments, and that hypomyopathic pa-
tients should be followed more closely to assess for disease pro-
gression over time. Larger trials are needed to identify long term
outcomes, optimal treatment, and whether treatment of spJDM
prevents weakness.
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Background
Musculoskeletal ultrasound (MSUS) is a well-established tool in the
diagnosis and management of inflammatory arthritis. The use among
pediatric rheumatologists, however, continues to be limited. The pur-
pose of this study was to assess the patterns of MSUS use among
North American pediatric rheumatologists and identify barriers im-
peding the wider acceptance of MSUS.
Methods
All Juvenile Idiopathic Arthritis (JIA) committee members of the
Childhood Arthritis and Rheumatology Research Alliance (CARRA)
from the United States and Canada were invited to complete an an-
onymous web-based survey designed to evaluate MSUS use. Ques-
tions focused on patterns of MSUS training, certification and
utilization, and ease of establishing an MSUS-based clinic. Attitudes
toward MSUS were solicited from practitioners not performing
ultrasound.
Results
The survey response rate was 58 of 204 (28 %). Of those pediatric
rheumatologists who responded, 25 (43 %) routinely perform MSUS,
5 (9 %) have received training in MSUS but do not actively use it, 16
(28 %) are interested in MSUS, while 12 (20 %) have no interest. All
but one (98 %) found MSUS to be a valuable tool for patient care.
Active sonographers (N = 25) tend to be within 10 years out of
fellowship (60 %) and primarily clinicians based at academic centers
(84 %). Duration of clinical practice varied from less than 1 year
(28 %), 2-5 years (68 %), and more than 6 years (4 %). Most attended
a formal training course (88 %) with American College of Rheumatol-
ogy (ACR) courses being most common. 10 (40 %) completed exten-
sive training through Ultrasound School of North American
Rheumatologists (USSONAR). Exposure in fellowship was limited
(28 %). Formal certification through ACR or the Canadian Rheumatol-
ogy Ultrasound Society (CRUS) was rare (8 % and 4 % respectively).
Most rheumatologist sonographers performed US at least weekly
(83 %) by incorporating US into routine appointments rather than
dedicated US clinics (83 vs 30 %). Primary indications for MSUS
included diagnosis synovitis (87 %) and joint injection guidance
(83 %). 65 % reported no difficulties starting US in their practice.
Main barriers included allocating clinic time for US (13 %) and
obtaining a machine (9 %). Institutional or radiology department
interference was rare (13 %); most report a supportive or indiffer-
ent relationship with radiology (78 %). Only 53 % of sonogra-
phers bill for MSUS with 23 % of them reporting difficulty with
receiving payment from insurers regardless of certification status.
Of non- sonographers, those with interest in MSUS training (N =
16) tend to be in the earlier phase of their career and dependent
on radiology to obtain US images rather than a rheumatologist
partner who performs MSUS. The major limitations to pursuing
MSUS training are the lack of time or financial support for train-
ing (75 %) and expense of equipment (62 %).Conclusions
MSUS use and interest among pediatric rheumatologists is likely
increasing. Barriers are not as widespread as once perceived. Survey
respondents were likely biased towards those who practice MSUS or
are supportive of the practice. Nevertheless, more pediatric-specific
MSUS training opportunities are needed.
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Background
Juvenile dermatomyositis (JDM) is the most common inflammatory
myopathy of childhood, with classic manifestations of symmetric
proximal muscle weakness and characteristic rash. Despite progress
in treatment, calcinosis remains a complication with steady incidence
despite improved outcomes in JDM. To date, there is no standardized
approach to the management of calcinosis and its various pheno-
types. To support the development of a future consensus treatment
plan, we sought to characterize physician perspectives of calcinosis
as it occurs in JDM. We hypothesized that based on physician experi-
ence and preference; there is variability in diagnostic approach, clas-
sification, and treatment strategies directly targeting calcinosis
(independent of JDM therapy).
Methods
After IRB exemption, an electronic survey was created using REDCap,
with 23 questions organized by section. Invitations to complete the
survey voluntarily and anonymously were sent to CARRA physician
members and the Pediatric Rheumatology Bulletin Board, an elec-
tronic list-serv. Analysis was by descriptive statistics.
Results
Of 139 survey responses, 135 met inclusion criteria by providing clin-
ical care to JDM patients less than 21 years of age. Only 106 fully
completed the survey, but 121 completed at least one section in
addition to demographics and were included in analysis. Of these, 91
(75 %) were CARRA members, a 30 % response rate. Pediatric rheu-
matologists comprised 95 % of respondents (U.S.-based totaled 75 %
with Europe at 14 %). 29 % of respondents are currently in or within
5 years of fellowship, and 26 % have more than 20 years of experi-
ence. The majority (61 %) has treated 10 or less JDM patients with
calcinosis and of these, 46 % have less than 15 years of experience.
Only 17 % of respondents have seen more than 20 cases of calcino-
sis, of which 75 % (12/16) have more than 20 years of experience. At
time of JDM diagnosis, 58 % use only history and/or physical exam
to screen for calcinosis, 23 % also use imaging and 8 % do no formal
assessment. Functional impairment and pain (84 %) were the most
common reasons to target calcinosis independent of other treatment
for JDM. Increasing systemic immune suppression was first line ther-
apy against calcinosis for 67 % (73/109). 24 % believe a surgeon
should evaluate every case of calcinosis if phenotype is amenable to
removal. To treat calcinosis, the most frequently used immunomodu-
lator was IVIG (56 %), which was also ranked most successful by
29 % (24/83). Bisphosphonates were the most common (72 %) and
ranked most successful (57 %) alternative therapy for calcinosis. IV
Sodium Thiosulfate was only used by 9 % (10/106), but was ranked
most successful by 30 % (3/10) of those who used it.
Conclusions
Calcinosis is a rare but morbid complication of JDM, and experience
treating calcinosis is low but varies among physicians. Screening
methods for calcinosis and the perceived relationship to active JDM
Pediatric Rheumatology 2016, Volume 14 Suppl 1 Page 11 of 16also vary, reflecting low rates of targeted calcinosis therapy separate
from overall disease treatment. IVIG and bisphosphonates are most
frequently used and considered most successful when treating calci-
nosis, but many other immunosuppressive and alternative agents are
utilized.
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Background
We compared 3 consensus treatment strategies in a prospective
cohort of children with dermatomyositis (JDM). The 3 strategies were:
1) MP – oral prednisone (pred) and subcutaneous methotrexate
(MTX), 2) MMP – intravenous pulse methylpredisolone (IVMP)
followed by pred and MTX, and 3) MMPI – intravenous immunuglo-
bulin (IVIG) along with IVMP, MTX and pred. Visits occurred at base-
line, 1, 2, 6, 12 and 18 months.
Results
The primary outcome was the feasibility of enrolling and follow-
ing subjects. Exploratory efficacy outcomes included physician
global scale (PhysGlob) at 2 months, and manual muscle testing
[MMT], childhood myositis scale [CMAS], and steroid dose at 2,
6, 12, and 18 months). Data were analyzed with models that
corrected for confounding by indication using Bayesian
methods.
Twelve sites enrolled between 1 and 6 subjects each (total n =
39). 27 subjects were white, 6 black, 2 Asian, 3 mixed race and
1 unknown. There were 25 girls and 14 boys. 13 subjects
(33 %) were treated with MP, 18 (46 %) with MMP, and 8
(21 %) with MMPI. After correcting for confounding by indica-
tion using a multinomial propensity score, the expected CMAS
(mean and 95 % credible interval) at 6 months was: MP 48.7
(46.0, 52.4), MMP 48.0 (45.2, 50.6), MMPI 45.1 (41.0, 50.0). Theprobability that MP results in better CMAS scores at 6 months
than MMP is 63 %, and the probability that MP is better than
MMPI is 90 %.
While these effectiveness estimates may serve in planning future
trials, it is possible that residual confounding by indication might
explain the differences we saw.
Conclusions
We conclude that it is feasible to use the CARRA CTP method to
study comparative effectiveness of treatments for children with
JDM.
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Background
Historically, osteomyelitis was considered an infectious disorder. More
recently, inflammatory mechanisms were recognized causing a signifi-
cant proportion of pediatric osteomyelitis. This study was to compare
demographics, presentation, treatment and outcomes in children with
chronic non-bacterial (CNO) or bacterial osteomyelitis (BOM).
Methods
A chart review of osteomyelitis patients from the departments of
pediatrics, pediatric surgery, orthopedic surgery, and oral and max-
illofacial surgery was conducted in a tertiary referral center, covering
the years 2004-2014.
Results
Incidences of CNO (n = 49) and BOM (n = 56) were comparable. Differ-
entiation between CNO and BOM based on clinical or laboratory find-
ings was mostly impossible. However, children with BOM more
frequently presented with local inflammatory signs (47 % vs. 68 %, p =
0.040), fever (12 % vs. 38 %, p = 0.003) and abscesses (0 % vs. 39 %, p
< 0.001). Peripheral arthritis (14 % vs. 0 %, p < 0.001), bowel disease
(10 % vs. 2 %, p = ns) and hyperostosis (29 % vs. 4 %, p = 0.001) were
more common in CNO. Whole body MRI was performed in 76 % of
CNO patients, unveiling multifocal lesions in 80 % (CRMO). CNO treat-
ment included NSAIDs, prednisolone, TNF-a inhibitors, and bisphospho-
nates. Over 50 % of CNO patients relapsed after a median of
30 months, while only 42 % sustained clinical remission after 5 years.
Conclusions
Though considered a rare disorder, institutional incidences of CNO
were comparable to BOM. This is of special importance, since long-
term outcomes in CNO were less favorable than previously sus-
pected. Particularly CRMO patients are at risk to develop arthritis and
sacroiliitis. Whole body MRIs should be performed in suspected CNO,
since clinically inapparent lesions are not uncommon. Prospective
studies are warranted to establish evidence-based diagnostic and
therapeutic approaches to CNO.
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Background
Systemic sclerosis (SSc) is a rare multisystem autoimmune disease
characterized by vasculopathy and organ fibrosis. From 2010-2013,
the North American CARRA Legacy Registry enrolled and prospect-
ively followed children with rheumatologic conditions including ju-
venile systemic sclerosis (jSSc). Objectives were to describe disease
manifestations, physician metrics, and patient quality of life (QOL) at
enrollment and follow up of jSSc subjects.
Methods
Descriptive statistics were used for demographic and clinical features.
Mann-Whitney U, Wilcoxon Signed Rank, Fisher’s exact, and McNe-
mar’s tests were used when appropriate for unpaired and paired
group comparisons.
Results
For the 64 children with SSc in the database, the majority were
female (84 %) and Caucasian (78 %); 86 % identified as non-
Hispanic. Median age of onset was 10.3 yr while age at first
pediatric rheumatology (PRH) evaluation was 11.8 yr, with 23 %
having a ≥2 yr delay to PRH. Baseline visit occurred a median of
3.6 yrs after disease onset. Forty-one children (64 %) had ≥ 1 fol-
low up visit recorded, and of those, 25 had a visit between 1 to
2 years after enrollment. For the cumulative 50.7 person years of
follow up, there were no mortalities or development of solid
organ manifestations (cardiac, pulmonary, renal) after baseline
visit. Based on available data, analysis of change in disease over
time was based on the 25 subjects with follow up visits within 1-
2 yrs after enrollment (median 1.4, IQR 1.05-1.88). To assess for
bias, baseline data for this group was compared to the remainder
of the cohort (n = 39) with no significant differences in demo-
graphics (gender, race, ethnicity) or time to care. Age of disease
onset was younger in our follow up subgroup, median 8.9 (IQR
5.1-11.8) years old versus 11.1 (IQR 8.1-14.3) years for those with-
out follow up (p = 0.027), which was similarly reflected in age at
baseline visit (median 13.4 versus 16.1, p = 0.03). Comparison of
the baseline data for the entire cohort (n = 64) to follow up data at 1-2
years (n = 25) is presented. Disease manifestations remained gen-
erally stable at follow up between these two groups. Paired ana-
lysis of baseline and follow up data for the n = 25 subgroup
revealed trends of decreased frequency of arthritis (4 to 1) and
increased joint contractures (7 to 11), decreased disability by ACR
Functional Class (44 % to 25 %), and improved median Physician
Global Disease Activity Score from 3 to 2.
Conclusions
While younger, our follow up subgroup was otherwise representa-
tive of our total cohort. Most organ manifestations were stable
with time and for the duration of the study observation period,
there was no interval development of major organ involvement
or mortality. While limited by the cross sectional nature of enroll-
ment, trends of improvement in disability and disease activity
were appreciated after 1-2 years of follow up.P26
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Background
Juvenile Idiopathic Arthritis (JIA) is a common chronic childhood
illness that causes inflamed and painful joints and can negatively im-
pact health-related quality of life (HRQL). Engaging children in their
treatment early on is important so that they are better prepared to
more independently manage the disease as they become adoles-
cents and young adults. While educational and self-management
programs exist for adolescents and adults with JIA, there are no such
programs for younger children. The aim of this study was to develop
and assess the usability of a bilingual (English and French) interactive
psycho-educational video game for 8 to 11 year old children with
JIA. The game modules played within 8-weeks on an iPad or desktop
computer aims to help children and parents learn disease manage-
ment and develop coping skills (e.g., dealing with physical symptoms
and feelings of stress or strong emotions) using gamification
mechanics.
Methods
The core game concept in which players battle physical (i.e., pain,
stiffness, and fatigue) symptoms and psychological (e.g., anger, frus-
tration) symptoms associated with JIA was developed in collabor-
ation with stakeholders. Five cycles of game usability testing have
been conducted with 19 English-speaking children (average age =
9.9 years; 12 female, 7 male) and 13 parents. One cycle of French
testing has been conducted (average age = 10 years, 1 male, 1 fe-
male, 2 parents). Participant interaction with the game proceeded in
a step-wise manner, with errors and efficiencies documented. Feed-
back from participants was also provided through a semi-structured
interview and these data were analyzed using content analyses.
Results
Overall, the response to the game has been positive. Minor sugges-
tions include changing specific graphics, adding more animation,
and reducing the amount of text, with no changes to core game me-
chanics. Some minor navigation errors (e.g., failure to locate func-
tions or follow the recommended screen flow) and presentation
errors (e.g., failure to correctly act upon desired information) were
documented. Based on participant feedback, English errors and effi-
ciencies were resolved after 5 cycles of testing. French usability test-
ing is ongoing.
Conclusions
There may be benefits from educational games for children with JIA
with regards to learning self-management strategies in order to im-
prove pain and HRQL. Based upon user suggestions, prototype
changes have been implemented and will continue to be tested. The
game has been translated into French and will be tested with
French-speaking participants. A pilot randomized control trial will as-
sess the feasibility and effectiveness of the game.
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Background
Juvenile idiopathic arthritis (JIA) is the most frequent cause of
chronic musculoskeletal pain in youth, and can negatively impact all
aspects of health-related quality of life. Self-management interven-
tions that provide individuals with disease-specific knowledge, strat-
egies to manage pain symptoms (e.g., cognitive-behavioural
therapies or CBT), and social support are needed to improve pain
and promote optimal health outcomes for adolescents with JIA. The
aim of this research is to design and develop a smartphone-based
pain self-management program, called iCanCopeTM, for youth living
with persistent pain related to JIA.
Methods
The iCanCopeTM program is being developed using a phased ap-
proach. In phase 1, we conducted a two-day consensus meeting
where experts in pediatric rheumatology, pain, and software devel-
opment, as well as patients developed standardized self-care pain
treatment algorithms for the app. In phase 2 (focus of this abstract),
we completed consultations with knowledge users and healthcare
providers to iterate the design concepts and features of the app. We
then created the iCanCope™ program prototype in collaboration with
the Centre for Global eHealth Innovation, including experts in human
factors and user experience. The prototype was then refined through
iterative consultations with knowledge users, as well as usability test-
ing using semi-structured, audio-recorded individual interviews with
youth with JIA.
Results
The iCanCope™ self-management app is designed to include four key
functions: (I) symptom reporting for the areas of pain/inflammation,
sleep, mood, physical activity, and energy; (II) personalized goal-
setting; (III) coping strategies toolbox including disease education
and in-the-moment accessible tools such as meditation; and (IV) so-
cial support in the form of a discussion forum which presents sched-
uled, curated questions for input from the app users. Usability
testing was completed in two cycles, in which feedback from know-
ledge users informed the refinement of functions presented in the
first cycle. Specific function refinements included (I) added introduc-
tory text for symptom tracking to clarify user expectations; (II) added
option for users to select from prepared goals in addition to creating
their own custom goals; (III) customized the types of coping strat-
egies that are presented based on user input; and (IV): restructured
the social support feature to differentiate from other existing social
media platforms and provide unique value. This second iteration of
the prototype was validated through usability testing by adolescents
with JIA (n = 2). End-users reported that this prototype was easy to
use and intuitive to navigate.
Conclusions
Smartphone technology has the potential to deliver tailored self-
management programming to youth with persistent pain due to JIA.
The next phase of this research will be to evaluate the feasibility of
the iCanCope™ app through a pilot randomized controlled trial with
adolescents with JIA across two pediatric rheumatology sites. If found
to be effective, the iCanCope™ self-management platform will be
adapted for other painful conditions and populations.P28
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Background
The United States pediatric rheumatology (PR) workforce is com-
mitted to a mission of providing children access to PR care [1].
With a limited number and distribution of pediatric rheumatolo-
gists, telemedicine has been proposed as a way to meet this mis-
sion [1]. The purpose of this study was to assess interest in
telemedicine and to determine which factors affect opinions
about this modality among parents/guardians of PR patients in
the Upper Midwest.
Methods
For six weeks in 2015, English-speaking guardians of patients
being evaluated at the University of Minnesota Pediatric
Rheumatology Clinic were eligible to participate in a needs-
assessment survey. Responses were analyzed using descriptive
statistics.
Results
Of 221 participants eligible for the survey, 159 (72 %) responded.
The majority were guardians of adolescent Caucasian patients
and had private insurance. The most common diagnosis was
juvenile idiopathic arthritis, and 28 % (45/159) traveled more than
three hours to the clinic. An overwhelming majority of respon-
dents (95 %, 144/152) reported a preference for in-person visits
over the option of telemedicine. Among 65 respondents who
reported travel to the clinic as inconvenient, 92 % still preferred
in-person visits. Compared to those for whom travel was not
inconvenient, those who indicated travel as inconvenient re-
ported significantly greater difficulty with several barriers to
accessing PR care – travel time/distance (p < 0.0001), need for
lodging/housing (p = 0.0047), driving in the metro (p < 0.0001), in-
direct costs (p < 0.0001), parent missing work (p < 0.0001), child
missing school (p = 0.0008), and arranging care for other children
(p = 0.0219). Nonetheless, preference for in-person visits was simi-
lar for both groups (convenient 97 %, inconvenient 92 %; p =
0.2881). Only 8 % (13/158) reported that they or a family mem-
ber or friend had ever used telemedicine, and this group was
more likely to report a preference for telemedicine (27 % vs 3 %;
p = 0.0087). This group was also more likely to report telemedi-
cine visits as better than or equal to in-person visits (42 % vs
8 %; p = 0.0033). Neither preference for in-person visits nor views
on telemedicine visits compared to in-person visits significantly
differed by patient demographics, insurance type, length of time
the child was a patient in the clinic, travel time, or frequency of
internet use.
Conclusions
Despite inconvenient travel and associated barriers, few respon-
dents preferred the option of telemedicine over in-person visits.
Familiarity with telemedicine was overall low but positively influ-
enced both a willingness to participate in and the assessment of
the quality of telemedicine. Sample bias existed because only
those who came to the PR clinic were surveyed. Efforts to in-
crease familiarity with telemedicine may foster increased accept-
ability. Additionally, other care modalities such as outreach
clinics, adult rheumatology care, and shared-care should be
explored as means to improve access to PR care.
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Background
CID is an important outcome measure for children with JIA. Sev-
eral demographic, phenotypic and serological factors have been
associated with aggressive disease. Early treatment with disease
modifying anti-rheumatic drugs (DMARD) and biologic agents
have led to favorable outcomes in arthritis in both adults and
children. However, the relationship of these factors or early treat-
ment with time to achieve CID has not been well studied in
children.
Objective
To determine the impact of demographic, phenotypic, serologic and
therapeutic factors on the time required to achieve CID in children
with JIA.
Methods
Demographic, disease subtype (using ILAR definitions), number of ac-
tive joints, medication use, lab tests for JIA patients enrolled in PR-
COIN (Pediatric Rheumatology Care and Outcomes Improvement
Network), a multicenter quality improvement collaborative between
1/2011 and 9/2015 were analyzed. Data was analyzed in Microsoft
Excel, using t test, correlation, regression and ANOVA. Statistical sig-
nificance was defined as p < 0.05.
Results
Of 272 patients 197 (72.4 %) achieved CID. Oligoarticular extended
(OJIA-E) subtype was associated with highest CID (88.8 %) and
rheumatoid factor positive (RF+) polyarticular JIA (POJIA) was associ-
ated with lowest CID (35.2 %) rates. There was no statistically signifi-
cant difference among disease subtypes in time required to achieve
CID (p = 4.48). Mean duration (t in months) to CID was comparable
(p = 1.63) in males (n = 48, t = 55.3) and females (n = 149, t = 65.1).
There was no statistically significant difference in time to CID in ANA
positive and negative patients with oligoarticular JIA. Time to start
DMARD from diagnosis showed positive correlation with time to CID
in all subtypes of JIA, with strongest correlation (r2 = 0.94) in systemic
JIA (SJIA) and enthesitis-related arthritis subgroups (r2 = 0.99). Time
to start biologic agents showed positive correlation with time to
achieve CID in OJIA-E (r2 = 0.92), RF negative POJIA (r2 = 0.87) and
SJIA (r2 = 0.58).
Conclusions
RF+ POJIA was associated with aggressive disease and with
least CID achievement. Gender, disease phenotype or ANA
serology were non-contributory to time to achieve CID. Early
treatment with DMARD and biologic agents led to faster
achievement of CID in most disease subtypes. Analysis of a
database with larger sample size will be performed next to con-
firm these findings.P30
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Fewer than 300 certified pediatric rheumatologists currently practice
in the United States. This shortage leads to lengthy waits for initial
appointments, often resulting in diagnostic delays. On the other
hand, many new patient visits are taken by children referred for non-
inflammatory musculoskeletal pain or nonspecific laboratory findings.
The pediatric rheumatology community has devoted much effort to
developing educational programs for pediatric trainees and general
pediatricians, but the efficacy of these programs has not been fully
assessed.
Objective
We aim to assess referral patterns to pediatric rheumatology, via a
review of chief complaints and diagnoses for new pediatric rheuma-
tology patients.
Methods
A retrospective study was performed of 151 new patient visits from
January to May 2015 to the pediatric rheumatology outpatient clinic
at Comer Children's Hospital of the University of Chicago. Data were
collected on patient sex, age, chief complaint and whether rheuma-
tology follow-up was recommended.
Results
Most new patients (60 %) did not have a confirmed rheumato-
logic diagnosis, and 40 % were requested to return for further
rheumatologic follow-up. Female patients were slightly more
likely to require rheumatologic follow up (44 %) vs male patients
(32 %). The most common presenting complaint was musculo-
skeletal pain, 41 %, followed by abnormal labs, 33 %. Rheumatol-
ogy follow-up was recommended for only 22 % of patients
presenting with musculoskeletal pain, and 33 % of those with ab-
normal lab testing. Joint swelling and fever were most predictive
of need further rheumatologic evaluation (83 % and 86 %
respectively).
Conclusions
At our center, musculoskeletal pain was the most common chief
complaint. Patients presenting with musculoskeletal pain were un-
likely to have a rheumatologic disease. These findings are consistent
with previous studies. Joint swelling and fever were most likely to be
associated with need for further rheumatologic evaluation. Encour-
agingly, in comparison with earlier investigations, a smaller propor-
tion of non-rheumatologic patients were referred to the pediatric
rheumatology clinic. However, a knowledge gap persists among
referring physicians, particularly with regard to the assessment of
rheumatologic vs non-rheumatologic musculoskeletal pain in
children.
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Background
Children represent about 15-20 % of the SLE population and accrue
a higher disease burden over a longer time. Consensus QI indicators
for cSLE were published in 2013. (1) Our recent work has targeted 2
of these: vaccination against influenza, pneumococcus, meningococ-
cus, and haemophilus influenza (Hib) and annual eye screening. We
report the rates at which our cSLE patients are up to date on eye
exams, immunizations, and documentation of patient education re-
lated to these goals.
Methods
All patients met the ACR 1982/1997 Revised Criteria for Classifica-
tion of SLE and were diagnosed before age 18. We used
immunization data from the Wisconsin Immunization Registry.
Data for eye exams was obtained manually. Previous work
Pediatric Rheumatology 2016, Volume 14 Suppl 1 Page 15 of 16created a pre visit planning (PVP) process to identify educational
topics that each patient needed and pertinent teaching materials
were given. A SLE specific flowsheet was implemented in our
electronic medical record to document education. In this cycle of
QI, the flowsheet was used to determine what education was
needed. In addition, we continued our system of immunization
reminders for pneumococcus and transferred this to include sea-
sonal influenza. Finally, we established the baseline immunization
rates for Hib, meningococcus and influenza.
Conclusions
Using both simple interventions and modifications of our elec-
tronic medical record (EMR), we were able to standardize the
care of our cSLE patients by systematically providing periodic
education regarding the importance of immunizations, eye
screening and reproductive health. We improved rates pneumo-
coccal immunization and established baseline immunization rates
for Hib, meningococcal and influenza immunization that will
allow us to track our progress in improving their rates of admin-
istration. Interestingly, rates for performance for all measures
were better than the rates for documentation of education. This
was most striking for Hib for which education rate was 24.5 %,
but the immunization rate was 86.8 %. The high immunization
rate for Hib, meningococcal and influenza vaccines reflects
administration in the primary care clinic in addition to the
rheumatology clinic, and if a provider sees that a vaccine was
performed, they are unlikely to perform re-education. In future
cycles of quality improvement, we plan to build on this success
to improve adherence to eye screening recommendations and
provision of reproductive health services to our cSLE patients. We
plan to leverage our EMR’s data collection and report functions
to make the process more efficient. This will allow us to take on
more quality improvement goals with the time and resources we
currently have available.P32
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Background
Consensus treatment plans (CTPs) for induction therapy of newly di-
agnosed proliferative lupus nephritis in juvenile SLE were published
by CARRA in March 2012 (Mina et al., Arthritis Care & Research). For
defining outcome measures (nephritis responsiveness and flare) in
these CTPs, pediatric rheumatologists selected the definitions from
the American College of Rheumatology (Arthritis Rheum. 2006) and
the European League against Rheumatism (Gordon et al., Lupus
2009). These definitions were originally developed for the study of
proliferative nephritis in adult SLE.
Methods
The objective of this study was to assess the level of agreement with
the definitions of nephritis responsiveness and flare among pediatric
nephrologists. A web- based survey was distributed to the member-
ship of the American Society for Pediatric Nephrology (ASPN) in
November 2015.Results
79 pediatric nephrologists completed all survey questions, which rep-
resents 15 % of practicing pediatric nephrologists in the United
States. Respondents practice at both small (33 %) and large pro-
grams (49 %, including 18 % from sites following >100 active SLE
patients) in all geographic regions. The number of years since
completion of fellowship was evenly distributed (8 % were in prac-
tice <2 yrs; 21 %, 2-5 yrs; 21 %, 5- 10 yrs; and 49 %, >10 yrs). Respon-
dents tended to either “strongly agree” or “somewhat agree” with
the CARRA definition for each level of responsiveness to therapy.
However, nephrologists were most likely to “strongly agree” with the
definition of substantial response or no response vs. “somewhat
agree” for intermediate responses. Only ~1/3 of respondents
“strongly agreed” with the CARRA definitions of proteinuric or neph-
ritic flares; “somewhat agree” was the most common response.
Conclusions
A general consensus exists between pediatric rheumatologists and
nephrologists in the definitions of response and flare in children be-
ing treated for proliferative lupus nephritis. However, there are gaps
in agreement that may be strengthened by the use of multi-
disciplinary teams in the development of future CTPs. A consensus
multi-disciplinary approach to managing these patients may result in
improved outcomes in pediatric SLE.
P33
The steroid taper app: Making of a mobile app
Jennifer M. P. Woo1, Marsha M. Malloy2, James A. Jegers4, Dustin J.
Hahn1, Mary K. Hintermeyer3, Stacey M. Martinetti2, Gretchen R. Heckel3,
Elizabeth L. Roth-Wojcicki2, Dominic O. Co2
1University of Wisconsin-Milwaukee, Milwaukee, WI, USA; 2Medical
College of Wisconsin, Milwaukee, WI, USA; 3Children’s Hospital of
Wisconsin, Milwaukee, WI, USA; 4Parent of patient, Milwaukee, WI, USA
Correspondence: Dominic O. Co (dco@mcw.edu) – Medical College of
Wisconsin, Milwaukee, WI, USA
Pediatric Rheumatology 2016, 14(Suppl 1):P33
Background
Long-term steroid regimens must be tapered gradually to prevent
adrenal insufficiency and/or flares of the underlying inflammatory
disease. These frequent changes in steroid dose can confuse pa-
tients and their families, leading to poor patient compliance.
Automation of the steroid tapering process could improve effi-
ciency and decrease variability of adherence and taper regimens.
As a result, we pursued the development of a mobile app to
address these issues and aid physicians in the prescription of
steroid tapers.
Methods
We surveyed a spectrum of care providers (both adult and
pediatric) representing different specialties and disciplines (e.g.,
nurses, physicians, advanced practice providers, pharmacists) to
assess needs. A patient’s father also joined our team for his per-
spective as a parent and his technical expertise as a software
engineer. After assessing available apps, we determined that an
app to calculate steroid tapers represented a gap in the market.
The collaboration between the Medical College of Wisconsin and
student developers from the University of Wisconsin-Milwaukee
“App Brewery” resulted in the development of an app for care
providers to calculate a taper and to generate a patient-friendly
calendar.
Results
We first defined the scope of version 1 of the Steroid Taper App and
triaged features for later versions. Next, we broke down the process
of steroid taper calculation into automatable steps. We then de-
signed the user interface for the provider and output for the patient.
We performed 18 development iterations over 22 months, to pro-
duce version 1 of the Steroid Taper App. The app will be publicly
available for iOS and android devices pending approval from the
iTunes and Google Play Stores.
Conclusions
Mobile apps have the potential to automate tedious but import-
ant tasks to deliver personalized healthcare and improve patient
Pediatric Rheumatology 2016, Volume 14 Suppl 1 Page 16 of 16outcomes. However, the app development process can be daunt-
ing for those without an information technology background.
Here we present our experience developing a mobile app that
automates calculation of steroid tapers and generates a patient-
friendly calendar that aims to improve compliance with steroid
tapers. We learned the value of engaging all stakeholders, which
in this case included patients/families and care providers of a
wide range of specialties and from across the continuum of care.We also learned the importance of limiting the scope of the ini-
tial version of the app while retaining the capacity and versatility
to accommodate new features. We hope that sharing our experi-
ence will help others who may be interested in developing a
mobile app of their own. In future work, we hope to see the app
evolve to include features such as consensus taper protocols and
more patient-centered features (i.e., integration into patients’
mobile device calendars and automated dose reminders).•  We accept pre-submission inquiries 
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